Lapemelanotide Monotherapy Shows Promising Efficacy In Melanoma Trial
Perspective Therapeutics reported 75% disease control rate with no serious adverse events in a Phase 1/2a study of [212Pb]lapemelanotide zapixetar (VMT01) at the 3.0 mCi dose.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed